πŸ›’ Your Cart

πŸš€ Free shipping on orders over $200  |  99%+ Purity Guaranteed  |  Same-Day Dispatch Before 2PM EST
πŸ“ US-Based Research Peptide Supplier  |  info@truetide.com
πŸ”₯ Metabolic & Fat Loss CAS: 221231-10-3 βœ“ 99%+ Purity

AOD-9604
Modified GH Fragment β€” Lipolytic Research Peptide

β˜…β˜…β˜…β˜…β˜…4.8 / 5  Β·  GRAS-designated, Phase II clinical data

Select Size

$69
5mg
βœ“
99%+ purity, independently verified by HPLC & mass spectrometry
❄
Lyophilized vials β€” shipped with cold pack, stable at βˆ’20Β°C long term
πŸ“„
Certificate of Analysis included with every order
🚚
Same-day dispatch on orders before 2PM EST
πŸ”’
Discreet, unmarked packaging β€” research-grade handling
⚠️ For Research Use Only. AOD-9604 is not approved for human consumption or therapeutic use. This product is sold exclusively as a research chemical for in vitro and laboratory research only.

What is AOD-9604?

AOD-9604 is a modified fragment of HGH (residues 176-191) with a Tyr substitution at position 176, designed to retain fat-burning properties while eliminating anabolic, diabetogenic, and receptor downregulation effects of full GH. It received FDA GRAS (Generally Recognized As Safe) designation and completed Phase II obesity trials, making it one of the most clinically validated peptides for isolated lipolysis research.

CAS 221231-10-3 | MW 1815.1 Da | FDA GRAS GRN 000240

Ξ²3-Adrenergic Lipolysis

Stimulates lipolysis via Ξ²3-adrenergic receptor-mediated pathway in adipocytes β€” independent of GHR signalling.

No Anabolic Activity

Does not bind the GH receptor for anabolic signalling. IGF-1 levels remain unchanged β€” essential control variable for fat research.

Glucose Neutral

No insulin resistance or hyperglycemia observed in Phase II trials β€” a key advantage over full GH in metabolic research.

Cartilage Research

Emerging data suggests AOD-9604 may stimulate cartilage repair via TGF-Ξ² independent of the GH axis β€” a secondary research application.

Phase IIb Weight Management Trial

Ng et al. demonstrated significant fat mass reduction with AOD-9604 in obese adults over 12 weeks, with no adverse metabolic effects. Phase II safety and efficacy data are among the strongest for any lipolytic peptide.

Int J Obes. 2000;24(7):871–879

FDA GRAS Designation

The comprehensive safety dossier submitted for GRAS notification confirmed AOD-9604's safety profile across acute, subchronic, and genetic toxicology studies.

FDA GRAS Notice GRN 000240

Cartilage Repair Research

Investigational studies showed AOD-9604 stimulated chondrocyte proliferation and proteoglycan synthesis in osteoarthritis models β€” expanding beyond its lipolytic research profile.

Osteoarthritis Cartilage. 2014;22(1):S10–S11

Research & Clinical Dosing

Phase II trials: 1mg (400Β΅g) - 9mg SC daily. Research protocols typically use 0.5–2mg ranges. In vitro adipocyte work: 10–100 nM. Endpoints: adipocyte size, lipid content (Oil Red O), lipolysis assay (glycerol release), body composition imaging.

Note: AOD-9604 and HGH Fragment 176-191 are structurally near-identical but differ in the Tyr modification. Products may vary by vendor β€” verify sequence.
Full NameAOD-9604 (Modified HGH Fragment 176-191)
CAS Number221231-10-3
Molecular Weight1815.1 Da
FDA StatusGRAS GRN 000240
Purityβ‰₯99% by HPLC
AppearanceWhite lyophilized powder
Storageβˆ’20Β°C, desiccated